Atorvastatin Calcium, Film Coated

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet.

12.1 Mechanism of Action Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles.

With Elimination kinetics span 8 to 17 hours per Atorvastatin Calcium, Film Coated clinical pharmacology residence kinetics and Consistent 51%–63% gastrointestinal absorption profile for Atorvastatin Calcium, Film Coated bioavailability, Atorvastatin Calcium, Film Coated undergoes systemic clearance of atorvastatin calcium, film coated integrates hepatic phase ii conjugation with renal filtration and establishes therapeutic activity over cmax attained 2–3 hours post-administration of atorvastatin calcium, film coated.

Standard adult regimens span 10 mg/1 Tablet, 20 mg/1 Tablet, 40 mg/1 Tablet, 80 mg/1 Tablet. Prescribers screen specifically against active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels hypersensitivity to any component of this medication pregnancy .; active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels ( 4 ).; hypersensitivity to any component of this medication ( 4 )., while community micro-logs most frequently note diarrhea (10.4% of reports), nausea (8.9% of reports), headache (7.3% of reports).